Does OFATUMUMAB Cause Product distribution issue? 104 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 104 reports of Product distribution issue have been filed in association with OFATUMUMAB (ARZERRA). This represents 0.4% of all adverse event reports for OFATUMUMAB.
104
Reports of Product distribution issue with OFATUMUMAB
0.4%
of all OFATUMUMAB reports
0
Deaths
12
Hospitalizations
How Dangerous Is Product distribution issue From OFATUMUMAB?
Of the 104 reports, 12 (11.5%) required hospitalization.
Is Product distribution issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OFATUMUMAB. However, 104 reports have been filed with the FAERS database.
What Other Side Effects Does OFATUMUMAB Cause?
Fatigue (5,202)
Headache (4,430)
Pain (3,382)
Chills (3,372)
Pyrexia (3,370)
Influenza like illness (2,727)
Nausea (1,688)
Multiple sclerosis relapse (1,525)
Covid-19 (1,435)
Asthenia (1,393)
What Other Drugs Cause Product distribution issue?
LENALIDOMIDE (858)
CERTOLIZUMAB PEGOL (403)
SECUKINUMAB (340)
RUXOLITINIB (301)
HUMAN IMMUNOGLOBULIN G (279)
POMALIDOMIDE (254)
RELUGOLIX (243)
VEDOLIZUMAB (150)
PIMAVANSERIN (134)
TEDUGLUTIDE (132)
Which OFATUMUMAB Alternatives Have Lower Product distribution issue Risk?
OFATUMUMAB vs OFLOXACIN
OFATUMUMAB vs OLANZAPINE
OFATUMUMAB vs OLANZAPINE\SAMIDORPHAN L-MALATE
OFATUMUMAB vs OLAPARIB
OFATUMUMAB vs OLARATUMAB